22 results about "Immune Stimulation" patented technology

Provided herein are immune stimulating anti-HBsAg antibody conjugates, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an HBV infection.

The present invention relates to a composition for enhancing immunity, containing Cheongwi-san as an active ingredient. The Cheongwi-san of the present invention is a mixed herbal medicine extract consisting of Cimicifuga heracleifolia, Moutan Radicis Cortex, Angelica gigas, Coptis Rhizome, and fresh root of Rehmannia glutinosa. The Cheongwi-san of the present invention has excellent effects of increasing the activity of NK cells, increasing the production amounts of IFN-γ and TNF-α, and reducing the survival rate of cancer cells, and has the effect of inhibiting influenza virus infection, and thus can be effectively used as a health functional food for enhancing immunity, a feed additive for animals for enhancing immunity, or a pharmaceutical product for preventing and treating diseases caused by decreased immunity.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

Provided in the present invention are an siRNA for inhibiting the expression of the activin A receptor type 1C (ACVR1C) gene, and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences set forth in SEQ ID NO: 1236-SEQ ID NO: 2470 by no more than 4 nucleotides. The antisense strand is 17-30 nucleotides in length; and the sense strand is 17-30 nucleotides in length, and is at least partially or completely complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention exhibit good stability, great ACVR1C gene inhibitory activity, and satisfactory cytotoxicity and immunostimulatory activity.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

Disclosed herein are systems and methods for selecting mesenchymal stem cells for clinical use. Particularly, in vitro co-culture methods and systems which characterize the response of immune cells (e.g., expression of IL-6, TNF-α, IL-1β) to immune challenges (e.g., LPS injection) as an assessment of the analgesic effect of mesenchymal stem cells.

The application discloses a preparation method of a trans-mucosal barrier and immune induction carrier based on amphoteric mannans, and belongs to the technical field of biological medicines. The application is based on a novel adjuvant mannans (MN) and a biodegradable polylactic acid-glycolic acid copolymer (PLGA). First, the mannans are modified to be amphoteric, and then the PLGA is chemically coupled by means of acyl chloride to form an amphiphilic copolymer. The copolymer is self-assembled into nanoparticles by means of ultrasonic method. The amphoteric mannans on the surface of the nanoparticle carrier can penetrate mucus, be taken up by cells and then stimulate immunity.

Provided in the present invention are an siRNA that inhibits AGT gene expression and a conjugate thereof. The siRNA contains a sense strand and an antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention have good stability, an excellent inhibitory activity against the AGT gene, and satisfactory cytotoxicity and immunostimulatory activities.

Compounds can specifically activate TLR7. The compounds are useful because they can stimulate innate immunity. The compounds can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, the composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. Pharmaceutical compositions contain the compound and preferably an additional compound such as imiquimod and / or resiquimod (R848). A composition contains the compound and a compound can be used as a medicament. Other aspects, embodiments, advantages and applications will become clear from the further description herein.

The invention relates to lymphocytes which are genetically engineered to overexpress one or more maintenance factor(s), wherein, as compared to a corresponding lymphocyte which is not engineered to overexpress said one or more maintenance factor(s), the lymphocytes exhibit enhanced stem-like or memory phenotype and a comparable or greater level of one or more effector functions in response to immune stimulation and a comparable or greater level of proliferation. The invention also relates to use of said lymphocytes in therapy, to methods for identifying said lymphocytes, and to methods for producing said lymphocytes.

The application discloses a modified alumina composite adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. The modified alumina composite adjuvant takes nano-alumina as a core, introduces a metal organic framework structure, is functionally modified by using a nano-drug carrier material, and forms the adjuvant with a multi-level core-shell structure. The structure enables the adjuvant to have a high encapsulation rate and good dispersion stability; meanwhile, the adjuvant can slowly release antigens in a physiological environment, prolongs the immune stimulation time, realizes intelligent release of the antigens in an acid or a microenvironment with specific enzymes, and thus better simulates a natural infection process and synergistically enhances an immune response. The application has a simple preparation process, mild conditions, good repeatability, a wide clinical application prospect and industrialization value.

The application discloses a kit for quantitatively detecting COVID-19 IFN-gamma by using peripheral blood and application thereof, and belongs to the technical field of biomedical testing. The kit provided by the application comprises blood stimulating reagents and an IFN-gamma detection kit, wherein the blood stimulating reagents comprise T cell epitope peptides, activators for enhancing the immune stimulation of T cells, and inhibitors for inhibiting the negative regulation of Treg cells. The kit can accurately detect whether a COVID-19 patient is effectively immunized after being cured and after being inoculated with a COVID-19 vaccine, has the advantages of good accuracy, high sensitivity, strong specificity, high stability, full-automatic detection and the like of the detection result, and has a good commercial application prospect in cell immune response detection.

The present application belongs to the technical field of genetic engineering, and particularly relates to a method for identifying the immune response function integrity of CD163 gene edited pig transformant macrophages. The present application provides a biomarker combination, which comprises a first primer pair for detecting the expression level of a TOX gene or a CD207 gene in an LPS stimulation group and a second primer pair for detecting the expression level of a SMPDL3B gene or a SLIT2 gene in a Poly(I:C) stimulation group, with RPS9 as the only internal reference gene. The present application does not require a wild type control individual, and can identify the immune response function integrity of macrophages of a single CD163 gene edited pig individual only by the gene activation amplitude of peripheral blood macrophages of the individual before and after immune stimulation.

In certain embodiments, the present invention provides immunostimulatory compositions, methods for making immunostimulatory compositions, and methods for using immunostimulatory compositions. In one aspect, provided herein is an immunostimulatory composition comprising: (a) a nanoparticle (NP), (b) an activating agent operably linked to the NP, and (c) a blood dendritic cell antigen 2 (BDCA2) ligand operably linked to the NP.

Provided are an siRNA conjugate targeting angiopoietin-like protein 4 (ANGPTL4) and use thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 contiguous nucleotides that differ by no more than 4 nucleotides from the nucleotide sequence shown in Table 1, and the antisense strand has a length of 17-30 nucleotides. The sense strand has a length of 17-30 nucleotides, and is at least partially complementary to the antisense strand. The siRNA conjugate and a pharmaceutical composition provided in the present invention have good stability, excellent ANGPTL4 gene inhibitory activity, and satisfactory immunostimulatory properties, and can significantly reduce the concentration of ANGPTL4 protein at the animal level.

This invention discloses a method for preparing a transmucosal barrier and immunomodulatory carrier based on amphoteric dextran, belonging to the field of biomedical technology. Based on the novel adjuvant dextran and polyphenol-metal complexation, this invention first modifies the dextran to amphoteric properties. Then, leveraging the self-assembly characteristics of polyphenols (such as tannic acid TA), metal ions (such as Ca²⁺) are further introduced. + Increased cross-linking strength drives DEX-CB to complex with active antigens, forming nanoparticles through self-assembly via hydrophobic and coordination interactions. These nanoparticles can load various antigens, and their surface amphoteric dextran can penetrate mucus, be taken up by cells, and thus stimulate the immune system.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The application provides a cell preparation based on vaccine pre-sensitization and CpG coupling and a preparation method thereof, the cell preparation comprising immune cells subjected to sensitization treatment by a pre-sensitization vaccine and an immune stimulator CpG coupled to the surface of the immune cells after the sensitization treatment; wherein the pre-sensitization vaccine comprises a whole antigen engineering nanovesicle, the whole antigen engineering nanovesicle carries an agonist of an interferon gene stimulatory receptor inside, and the whole antigen engineering nanovesicle is derived from tumor cells. The CpG-loaded vaccine pre-sensitized T cells (CpG@VT) of the application can stimulate an anti-tumor immune cell promotion type reaction enhancement in a co-stimulation mode of effect T cell targeted delivery, direct killing and CpG-induced immunogenic death (ICD).

The application provides an RVG29 modified bacterial outer membrane vesicle and a preparation method and application thereof, the RVG29 modified bacterial outer membrane vesicle carries a rabies virus glycoprotein derivative peptide 29, and the amino acid sequence of the rabies virus glypoprotein derivative peptide 29 is shown as SEQ ID No: 1. The application constructs a BEV (bacterial outer membrane vesicle) expressing RVG29 on the surface, namely BEV-RVG29, by a genetic engineering method, the BEV-RVG29 can efficiently cross the BBB (blood-brain barrier) in vitro and in vivo and is enriched at a tumor site. The application further provides a pharmaceutical composition, the pharmaceutical composition is formed by loading paclitaxel on the BEV-RVG29 to form a nano delivery system, and in the pharmaceutical composition, the immune stimulation characteristics of the BEV-RVG29 itself and the immunogenic cell death induced by PTX (paclitaxel) produce a synergistic effect, so that the growth of a glioblastoma is significantly inhibited.